

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

NCT07223593

Status	RECRUITING
Phase	Phase 3
Sponsor	Eli Lilly and Company
Enrollment	1,205 participants

Key Eligibility Criteria

Inclusion (2)

- Have symptomatic PAD with intermittent claudication of Fontaine Stage II
- Have an Ankle Brachial Index (ABI) of 0.9 or less

Exclusion (7)

- Have a body mass index (BMI) less than 23 kilogram per square meter (kg/m²)
- Have Hemoglobin A1c (HbA1c) greater than 10%
- Have walking ability limited by conditions other than PAD
- Have a planned lower limb surgery or any other surgery affecting walking ability
- Had peripheral revascularization procedure within 90 days prior to the day of screening or planning to undergo peripheral revascularization during the clinical trial

... and 2 more (see full listing online)

Locations (139 total)

St. Vincent's Birmingham Hospital, Birmingham, Alabama, United States
Mercy Gilbert Medical Center, Gilbert, Arizona, United States
Axsendo Clinical Research - Peak Heart & Vascular - Surprise, Surprise, Arizona, United States
... and 136 more locations